Management of mitral stenosis during pregnancy

Authors

  • Gleiny Vazquez Hernández Hospital Ginecobstétrico Ramón González Coro https://orcid.org/0000-0003-4060-352X
  • Román Vasallo Peraza
  • Pedro Antonio Román Rubio
  • Yilena Gil Jimenez
  • Mónica Meluzá Martín
  • Yaima Gallinat Martín

Keywords:

mitral stenosis, pregnancy

Abstract

Heart disease complicates about 4% of pregnancies; and represent the leading non-obstetric cause of maternal death. Valvular lesions have a high prevalence, being mitral stenosis the one with the worst prognosis during pregnancy. This article aims to present the recommendations of the National Heart Disease and Pregnancy Service for the management of mitral stenosis during pregnancy. Evaluation of valve anatomy and disease severity is crucial. Moderate to severe injuries should be treated with cardioselective beta-blockers and elective percutaneous commissurotomy, if the anatomy is favorable. If there is volume retention, diuretics are indicated. Among the drugs for obstetric use, prostaglandins, nifedipine and fenoterol are contraindicated. The time of termination of pregnancy depends on the gestational age and the appearance of signs of maternal or fetal decompensation, in which case they have an indication for cesarean section.

Downloads

Download data is not yet available.

Author Biography

Gleiny Vazquez Hernández, Hospital Ginecobstétrico Ramón González Coro

Servicio Nacional de Cardiopatía y Embarazo

References

Referencias bibliográficas.

1. Samuel Avila W, Giunco Alexandre R, de Castro M, et al. Posicionamento da Sociedade Brasileira de Cardiologia para

Gravidez e Planejamento Familiar na Mulher Portadora de

Cardiopatia – 2020. Arq.Bras. Cardiol.2020; 114(5): 849-942. Disponible en: https: //doi.org/10.36660/abc.20200406

2. ACOG practice bulletin No. 212: pregnancy and

heart disease. Obstet Gynecol 2019;133:e320–56. Disponible en: https: //pubmed.ncbi.nlm.nih.gov/310222123

3. Lewey J, Andrade L, Levine L. Valvular Heart Disease in

Pregnancy. Cardiol Clin 39 (2021) 151–161. Disponible en: https://doi.org/10.1016/j.ccl.2020.09.010

4. Muryán S, Malvino E. Cuidados intensivos cardiológicos en pacientes obstétricas. Vol V. 2aed. Argentina; 2020. P. 121-125. Disponible en: www.obstetriciacritica.com

5. Archivos del Servicio Nacional de Cardiopatía y Embarazo (SNCE). 2000-2021. Hospital Ramón Gonzalez Coro.

6. Ki Park, MD, Bairey C, Bello N, Davis M, et al. Management ofWomen With AcquiredCardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum. JACC VOL. 77, NO. 14, 2021: 1 7 9 9 – 8 1 2. Disponible en: https://doi.org/10.1016/j.jacc.2021.01.057

7. Regitz V, Roos J, Bauersachs J, et al. Guía ESC 2018 sobre el tratamiento de las enfermedades cardiovasculares durante el embarazo. Rev Esp Cardiol. 2019;72(2):161.e1-e65. Disponible en: http://doi.org/10.1016/j.recesp.2018.12.004

8. Guimarães T, Magalhães A, Veiga A, et al. Cardiopatia e gravidez, o estado da arte. Rev Port Cardiol. 2019;38(5):373---383. Disponible en: https://doi.org/10.1016/j.repc.2018.05.013

9. Sharma G, Ying W, Silversides C. The Importance of Cardiovascular Risk Assessment and Pregnancy Heart Team in the Management of Cardiovascular Disease in Pregnancy Cardiol Clin 39 (2021) 7–19. Disponible en: https://doi.org/10.1016/j.ccl.2020.09.002

10. U.S. Department of Health and Human Services, Food

and Drug Administration, Center for Drug Evaluation and

Research, Center for Biologics Evaluation and Research.

Reviewer guidance: evaluating the risks of drug exposure in

human pregnancies.

11. Ersboll AS, Hedegaard M, Sondergaard L, Ersboll M, Johansen M.Treatment with oral betablockers during pregnancy complicated bymaternal heart disease increases the risk of fetal growth restriction. BJOG.2014; 121(5):618-26

12. Bianchi A, Blasina F, Castillo E, et al. Glucocorticoides prenatales. Documento uruguayo de consenso. Archi Pediatr Urug 2018; 83(3):179-186. Disponible en: https://dx.doi.org/10.31134/AP.89.3.5

13. 2020 ACC/AHA Guideline for the Management

of Patients With Valvular Heart Disease. Circulation. 2021;143:e00–e00. DOI: 10.1161/CIR.0000000000000923

14. Surabhi N, Catherine N, Mackillop L. Cardiac disease in pregnancy. Clinical Medicine 2012, Vol 12, No 6: 553–560. Disponible en: https://dx.doi.org/ 10.7861/clinimedicine.12-6-553.

15. Del Pilar Alvares M, Diaz Carrillo MA. Insuficiencia cardiaca aguda secundaria a estenosis mitral reumática durante el puerperio. Med Crit 2018,32 (3):160-163. Disponible en: http://www.medigraphic.com/medicinacritica

16. Laxmi S, Mehta M, Chair C, Warner M, et al. Cardiovascular Considerations in Caring for Pregnant Patients A Scientific Statement From the American Heart Association. Circulation. 2020;141:e884–e903. DOI: 10.1161/CIR.0000000000000772. Disponible en: https://www.ahajournals.org/journal/circ

Published

2022-08-02

How to Cite

1.
Vazquez Hernández G, Vasallo Peraza R, Román Rubio PA, Gil Jimenez Y, Meluzá Martín M, Gallinat Martín Y. Management of mitral stenosis during pregnancy. Rev Cubana Inv Bioméd [Internet]. 2022 Aug. 2 [cited 2025 Jul. 12];41. Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/2423

Issue

Section

ARTÍCULOS ORIGINALES